Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

(2017) David Z I Cherney et al.   Lancet Diabetes & Endocrinology

Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus

(2016) Hiddo J.L. Heerspink et al.   CIRCULATION

Sodium glucose cotransporter 2 inhibition in the diabetic kidney

(2016) Aleksandra Novikov et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Increased grip strength with sodium-glucose cotransporter 2

(2016) Motoaki Sano et al.   Journal of Diabetes

Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation

(2015) Nobutaka Nakamura et al.   Diabetology & Metabolic Syndrome

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

(2011) Giovanni Musso et al.   ANNALS OF MEDICINE

Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy

(2011) Masanori Abe et al.   Journal of Atherosclerosis and Thrombosis

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES